ESMO BC 2024

ESMO BC 2024
May 15-17, 2024
Berlin, Germany

European Society for Medical Oncology Breast Cancer 2024.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (2)

    Efficacy of sacituzumab govitecan versus treatment of physicians' choice in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: A meta-analysis of TROPiCS-02 and EVER-132-002 trials 

    • Author(s): Gluz, O
    • trodelvy
    • Oncology
    • Trop-2
    • HR+/HER2-
    • EVER-132-002
    • meta-analysis
    • Asia
    • CDK4/6i

    The impact of high body mass index on the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from ASCENT

    • Author(s): Estévez, L
    • trodelvy
    • Oncology
    • mTNBC
    • ASCENT
    • Body Mass Index (BMI)
    • Weight
    • Underweight
    • Overweight
    • Obese